WNK1/HSN2 mediates neurite outgrowth and differentiation via a OSR1/GSK3β-LHX8 pathway

Masahiro Shimizu & Hiroshi Shibuya

With no lysine kinase 1 (WNK1) phosphorylates and activates STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) and oxidative stress responsive kinase 1 (OSR1) to regulate ion homeostasis in the kidney. Mutations in WNK1 result in dysregulation of the WNK1-SPAK/OSR1 pathway and cause pseudohypoaldosteronism type II (PHAII), a form of hypertension. WNK1 is also involved in the autosomal recessive neuropathy, hereditary sensory and autonomic neuropathy type II (HSANII). Mutations in a neural-specific splice variant of WNK1 (HSN2) cause HSANII. However, the mechanisms underlying HSN2 regulation in neurons and effects of HSN2 mutants remain unclear. Here, we found that HSN2 regulated neurite outgrowth through OSR1 activation and glycogen synthase kinase 3β (GSK3β). Moreover, HSN2-OSR1 and HSN2-GSK3β signalling induced expression of LIM homeobox 8 (Lhx8), which is a key regulator of cholinergic neural function. The HSN2-OSR1/GSK3β-LHX8 pathway is therefore important for neurite outgrowth. Consistently, HSN2 mutants reported in HSANII patients suppressed SPAK and OSR1 activation and LHX8 induction. Interestingly, HSN2 mutants also suppressed neurite outgrowth by preventing interaction of between wild-type HSN2 and GSK3β. These results indicate that HSN2 mutants cause dysregulation of neurite outgrowth via GSK3β in the HSN2 and/or WNK1 pathways.

The with no lysine (WNK) family of serine/threonine protein kinases is conserved in many species. There are four mammalian WNK family members, WNK1–4, and mutations in WNK1 and WNK4 cause a hereditary form of hypertension, pseudohypoaldosteronism type II (PHAII). WNK1 and WNK4 phosphorylate and activate SPAK and OSR1 kinases, which subsequently induces activation of ion co-transporters, such as NKCC1, NKCC2 and NCC in the kidney. Moreover, Wnk4D561A knockin mice exhibit phenotypes similar to PHAII. These data indicate that dysregulation of the WNK-SPAK/OSR1 pathway causes unbalanced ion homeostasis and results in hypertension with hyperkalaemia in PHAII patients. The HSN1 has auto-inhibitory domain and this domain inhibits WNK1 auto-phosphorylation and phosphorylation of its substrate. Similarly, the WNK4 also has auto-inhibitory domain and this domain suppresses WNK1 auto-phosphorylation and activation. These findings suggest that the WNK kinases modulate the kinase activity of other WNK family members. In fact, there is a report that WNK1 forms complexes with WNK1 and WNK4 and this interaction is important for the function of WNK1 activating downstream effectors. Furthermore, it has been reported that WNK2 and WNK3 also bind to WNK1 and phosphorylate WNK1 inducing the activation of SPAK/OSR1. These data suggest that the interaction between WNK family members have essential roles in WNK-SPAK/OSR1 pathway.

A neuron-specific WNK1 splice variant, called HSN2, is expressed in the brain, dorsal root ganglia and sciatic nerve. Mutations in a neural specific exon of HSN2 cause the hereditary neuropathy, hereditary sensory and autonomic neuropathy type II (HSANII). HSANII is an autosomal recessive neuropathy characterized by sensory dysfunction, such as loss of pain, touch and temperature sensation and limb abnormalities, such as finger deformity and Charcot's joint. Knockdown of HSN2 enhances K⁺-Cl⁻ cotransporter 2 (KCC2) expression and leads to abnormal neuromast development in zebrafish embryos. Moreover, a knockout mouse lacking the Hsn2 exon of Wnk1 showed reduced pain hypersensitivity and restored γ-aminobutyric acid (GABA)-mediated depolarization after nerve injury. Although these reports indicate that HSN2 mutants cause HSANII is still unclear.

LIM homeobox 8 (LHX8) is a LIM homeobox transcription factor and a key regulator of cholinergic neural function. LHX8 is also involved in the determination of cholinergic or GABAergic cell fate. Furthermore, LHX8 is required for cholinergic neurons in the ventral forebrain. Consistent with these observations, we have reported that WNK1 and WNK4 induce LHX8 through OSR1 and GSK3β and that this signalling pathway
is important for neurite outgrowth\textsuperscript{28,29}. These findings indicate that not only WNK1 but also HSN2 regulates neurite outgrowth via LHx8 induced by OSR1 and GSK3\(\beta\).

In this study, we analysed HSN2 functions in the OSR1-LHX8 pathway. We found that HSN2 was involved in the phosphorylation of SPAK and OSR1 and induced LHx8 expression to modulate neurite outgrowth identically to WNK1. We also demonstrated that HSN2 mutants suppressed OSR1 activation, LHx8 expression and effects of GSK3\(\beta\) on neurite outgrowth. These results reveal a novel role of HSN2 in neurite outgrowth and help to elucidate the pathogenic mechanism of HSANII.

**Results**

**Wild-type but not mutant HSN2 binds to WNK1, WNK4, SPAK, OSR1 and HSN2.** HSN2 is a neural specific isoform of WNK1, and mutations in HSN2 cause the autosomal recessive neuropathy, HSANII\textsuperscript{14}. WNK1 can form complexes with WNK1 and WNK4 to activate downstream effectors\textsuperscript{12}. To analyse whether HSN2 binds to WNK1 and WNK4, we transiently expressed HA-tagged WNK1 and HSN2 with Myc-tagged WNK1 or WNK4 in HEK293T cells. Cell extracts were immunoprecipitated with a Myc antibody and immunoprecipitates were subjected to immunoblotting. As shown in Fig. 1A, B, HSN2 bound similarly to WNK1 and WNK4. In HSANII patients, mutations have been identified in the neural-specific alternatively spliced exon of HSN2, including a 1-bp deletion (2743delA\textsuperscript{14}, referred to as HSN2-delA) and a 1-bp insertion (3237_3238insT\textsuperscript{19}, referred to as HSN2-insT). These mutations cause a frameshift and result in truncated HSN2 proteins at amino acid 916 and 1080, respectively. We also checked the binding of these HSN2 mutants to WNK1 and WNK4 and found that they could not interact with WNK1 or WNK4 (Fig. 1A, B). WNK1 interacts with and phosphorylates the STE20 kinases, SPAK and OSR1, to activate the downstream pathway\textsuperscript{5,6}; therefore, we analysed the binding of HSN2 and its mutants to SPAK and OSR1. We found that HSN2 and WNK1 bound similarly to SPAK and OSR1, but the binding of HSN2 mutants to SPAK and OSR1 was weak compared with that of WNK1 and HSN2 (Fig. 1C, D). Interestingly, HSN2 also bound to itself, but HSN2-delA and HSN2-insT could not bind to wild-type HSN2 (Fig. 1E). These results indicate that HSN2-delA and HSN2-insT mutants are unable to promote activation of downstream signalling because the HSN2 mutants could not interact with HSN2, WNK1, WNK4 or SPAK/OSR1 (Fig. 1F).

**HSN2 mutants, HSN2-delA and HSN2-insT, exhibit loss of neurite outgrowth function.** We previously reported that WNK1 and WNK4 are involved in induction of neural marker genes and neurite elongation in mouse neuroblastoma Neuro2A cells\textsuperscript{28,29}. HSN2 may, therefore, have similar functions in neurite outgrowth and HSN2 mutants may exhibit loss of function. To examine whether HSN2 is involved in neurite outgrowth, we transiently expressed HSN2 in Neuro2A cells and observed that HSN2 induced neurite elongation identically to WNK1 (Fig. 2A upper panel). We then examined the effect of HSN2 mutants on neurite outgrowth. As shown in Fig. 2A, HSN2-delA and HSN2-insT mutants could not induce neurite elongation. Next, we checked the effects of wild-type and mutant HSN2 on neurite outgrowth induced by nerve growth factor (NGF). HSN2 constructs were transfected into Neuro2A cells and 24 h later cells were treated with serum-free medium containing 100 ng/ml NGF for 24 h. This treatment induced neurite elongation, and the expression of WNK1 or HSN2 enhanced this induction (Fig. 2A lower panel). In contrast, the expression of HSN2-delA or HSN2-insT suppressed neurite elongation in response to NGF-containing medium (Fig. 2A lower panel). We also analysed the expression of neural marker genes, LHx8 and Choline acetyltransferase (ChAT) for cholinergic neurons and Glutamine acid decarboxylase 1 (Gad1) for GABAergic neurons. qPCR analysis indicated that NGF treatment greatly induced the expression of LHx8, ChAT and Gad1, and that exogenous expression of WNK1 or HSN2 induced LHx8 and ChAT expression (Fig. 2B). WNK1 and HSN2 enhanced NGF-mediated expression of LHx8 and ChAT, but reduced that of Gad1. In contrast, expression of HSN2-delA and HSN2-insT mutants decreased LHx8 and ChAT expression and increased Gad1 expression (Fig. 2B). These results indicate that WNK1 and HSN2 are involved in neurite outgrowth, but that HSN2-delA and HSN2-insT mutants fail in this activity. Interestingly, HSN2 mutants inhibited NGF-independent WNK1- and HSN2-mediated neurite elongation (Fig. 2C), suggesting that these mutants have a dominant negative effect on wild-type WNK1 and/or HSN2.

We next analyzed the effect of knockdown of Wnk1 and Wnk4 on neurite elongation of Neuro2A cells. We confirmed that treatment of siWnk1 and siWnk4 downregulated the expression of Wnk1 and Wnk4 in Neuro2A cells, respectively (Supplementary Fig. 1A). Since Hsn2 gene includes the target sequence of siWnk1, siWnk1 treatment has also reduced the expression of Hsn2 (Supplementary Fig. 1A). While neurite elongation was suppressed by treatment of only siWnk1, but not siWnk4, the knockdown of both Wnk1 and Wnk4 more inhibited neurite elongation of Neuro2A cells (Supplementary Fig. 1B). To clarify this issue, we checked the endogenous expression levels of these genes in Neuro2A cells, and found that Wnk4 and Hsn2 mRNA were expressed at very low levels compared with Wnk1 expression (Supplementary Fig. 1C). Especially, Wnk4 expression level was less than one-thousandth of Wnk1. These results suggest that the knockdown of only Wnk1 has no effect on neurite elongation, because Wnk4 expression is very weak in Neuro2A cells. In addition, Wnk4 might have some functions for enhancing Wnk1 functions in neurite elongation of Neuro2A. We therefore used the both of siWnk1 and siWnk4, because the knockdown of both Wnk1 and Wnk4 was the most effective for inhibiting neurite elongation. Moreover, we also analyzed whether Wnk1 and Wnk4 have redundancy in function of neurite elongation and found that Wnk4 rescued the suppression of neurite elongation and neural marker genes caused by knockdown of only Wnk1 and both Wnk1 and Wnk4 in Neuro2A cells (Supplementary Fig. 1D, E). This suggests that Wnk4 has functional redundancy with Wnk1 in neurite outgrowth of Neuro2A cells.

As shown in Fig. 2D, siWnk1 and siWnk4 treatment suppressed NGF-containing serum-free medium-mediated neurite elongation in Neuro2A cells. Moreover, knockdown of Wnk1 and Wnk4 suppressed LHx8 and ChAT expression, and induced Gad1 expression (Fig. 2E), indicating that WNK proteins are required for
neurite outgrowth of Neuro2A cells, as previously reported\textsuperscript{28,29}. We next examined whether expression of HSN2 constructs could rescue these effects. We found that expression of WNK1 or HSN2 rescued neurite elongation and expression of neural marker genes (Fig. 2D,E). In contrast, these rescue effects were not observed with HSN2-delA or HSN2-insT mutants (Fig. 2D,E). These data indicate that HSN2 mutants fail to exert the normal functions of WNK1/HSN2 in neurite outgrowth.
Figure 2. HSN2 mutants, HSN2-delA and HSN2-insT, exhibit loss of neurite outgrowth function. (A) Neurite outgrowth from Neuro2A cells treated with NGF (100 ng/ml) or vehicle-containing FBS-free medium for 24 h. Cells were transiently transfected with pRK5, HA-WNK1, HA-HSN2, HA-HSN2-delA or HA-HSN2-insT vectors 24 h prior to treatment. (B) RT-PCR and qPCR analysis of mRNA levels of neural marker genes, Lhx8, ChAT and Gad1, in Neuro2A cells indicated in (A). The value of each gene in empty vector-transfected, vehicle-treated cells was set to 1 and the value in empty vector-transfected, NGF-treated cells was set to 100. (C) Neurite elongation of Neuro2A cells 24 h after transfection of HA-WNK1 or HA-HSN2 with pRK5, HA-HSN2-delA or HA-HSN2-insT vectors. (D) Neurite outgrowth of Neuro2A cells treated with 100 ng/ml NGF-containing FBS-free medium for 24 h. Cells were transiently transfected with control siRNA (siCTL) or siWnk1 and siWnk4 24 h prior to treatment. (E) RT-PCR and qPCR analysis of mRNA levels of Lhx8, ChAT and Gad1 in Neuro2A cells indicated in (C). The value of each gene from vehicle-treated cells under siCTL treatment and from NGF-treated cells under siCTL treatment was set to 1 and 100, respectively.
NGF activates SPAK/OSR1 through WNK1 and HSN2. To analyse whether HSN2 regulates activation of SPAK and OSR1 in neurite outgrowth, we checked phosphorylation of SPAK and OSR1 in Neuro2A cells treated with NGF-containing serum-free medium. The phosphorylation of SPAK and OSR1 was observed at 10 to 15 min after treatment with NGF-containing medium (Fig. 3A). In contrast, knockdown of either Wnk1 or Wnk4 suppressed the phosphorylation of SPAK and OSR1 by NGF (Fig. 3B). Moreover, knockdown of both Wnk1 and Wnk4 strongly inhibited SPAK and OSR1 phosphorylation (Fig. 3B). We also checked the phosphorylation of CATCHtide peptide by OSR1 with treatment of peptide, because the CATCHtide was reported as a peptide substrate of SPAK and OSR1.\(^a\) Analysis of SDS-PAGE including Phos-tag showed that OSR1 from NGF-treated Neuro2A cells induced an electrophoretic mobility shift of CATCHtide indicating the phosphorylation of CATCHtide (Supplementary Fig. 2). These findings demonstrate that NGF activates the WNK-SPAK/OSR1 pathway in Neuro2A cells. We next analysed the effect of HSN2 on the phosphorylation of SPAK and OSR1 mediated by NGF. We found that HSN2 expression increased the level of SPAK and OSR1 phosphorylation identically to that following Wnk1 expression (Fig. 3C). By contrast, the expression of HSN2-delA and HSN2-insT mutants suppressed the NGF-induced phosphorylation of SPAK and OSR1 (Fig. 3C). These results indicate that HSN2 mutants cannot activate SPAK and OSR1 and work in a dominant negative manner. These data are consistent with the neurite elongation and neural marker gene expression results (Fig. 1A–C).

We previously demonstrated that the WNK1-OSR1 pathway is involved in neurite outgrowth.\(^b\) To confirm whether NGF-induced neurite outgrowth is mediated by the HSN2-OSR1 pathway, we examined the effect of Osr1 knockdown on neurite outgrowth. As expected, Wnk1 expression enhanced neurite outgrowth induced by NGF treatment, and knockdown of Osr1 inhibited this elongation (Fig. 3D). Similar results were obtained with HSN2 expression and knockdown of Osr1 (Fig. 3D). In contrast, expression of HSN2 mutants suppressed NGF-induced neurite elongation, and knockdown of Osr1 completely inhibited neurite outgrowth (Fig. 3D). RT-PCR and qPCR analysis showed that NGF-induced Lhx8 and Chat expression was completely suppressed by Osr1 knockdown even though Wnk1 or HSN2 was expressed in Neuro2A cells (Fig. 3E). Moreover, although NGF-induced Gad1 expression was reduced by Wnk1 or HSN2 expression, knockdown of Osr1 rescued this reduction (Fig. 3E). We also examined the effect of a kinase-negative form of OSR1 (OSR1\(^{K46M}\)) and similar results were obtained to those with Osr1 knockdown (Fig. 3F,G). These results demonstrate that NGF-induced neurite outgrowth via Wnk1 and HSN2 require OSR1 activity.

The HSN2-OSR1-LHX8 pathway is important for NGF-induced neurite outgrowth. LHX8 is a key regulator of cholinergic neural function and is involved in the determination of cholinergic and GABAergic cell fate.\(^c\) We previously demonstrated that the WNK1-OSR1 pathway is important for Lhx8 expression.\(^b\) To determine whether Lhx8 expression is mediated by the HSN2-OSR1 pathway, we examined the effects of HSN2 constructs on Neuro2A cells in the absence of NGF stimulation. We confirmed that expression of Wnk1 or HSN2 mediated Lhx8 induction, and that knockdown of Osr1 suppressed this induction (Fig. 4A). We also examined the effect of a kinase-negative OSR1\(^{K46M}\) mutant on Lhx8 expression, and found that OSR1\(^{K46M}\) also suppressed Lhx8 expression induced by Wnk1 or HSN2 expression (Fig. 4B). In contrast, HSN2-delA and HSN2-insT did not induce Lhx8 expression (Fig. 4A,B). We next analysed whether NGF-induced neurite outgrowth in Neuro2A cells is mediated by Lhx8. Lhx8 knockdown inhibited not only Wnk1-, but also HSN2-induced neurite outgrowth (Fig. 4C). Furthermore, although the expression of HSN2 caused an increase in Chat expression and a decrease in Gad1 expression, knockdown of Lhx8 suppressed Chat expression and enhanced Gad1 expression by the expression of HSN2 (Fig. 4D). These results indicate that HSN2-induced neurite outgrowth, including neurite elongation and expression of cholinergic neuron marker genes, was mediated by Lhx8 through OSR1 activity.

HSN2 mutants suppress neurite outgrowth via GSK3β. GSK3β is a positive effector of WNK signalling in neurite outgrowth.\(^d\) To confirm whether HSN2 mediates NGF-induced neurite outgrowth through GSK3β, we examined the effect of Gsk3β knockdown on neurite outgrowth of Neuro2A cells. As shown in Fig. 5A, WNK1- and HSN2-mediated neurite elongation was suppressed by siGsk3β treatment. Moreover, HSN2 mutants suppressed NGF-induced neurite elongation, and knockdown of Gsk3β completely inhibited neurite outgrowth (Fig. 5A). We also analysed expression of neural marker genes in Neuro2A cells and found that Gsk3β knockdown suppressed NGF-induced Lhx8 and Chat expression, even though Wnk1 or HSN2 was expressed (Fig. 5B). Furthermore, although Wnk1 or HSN2 expression decreased NGF-induced Gad1 expression, knockdown of Gsk3β rescued this reduction (Fig. 5B). These results demonstrate that NGF-induced neurite outgrowth via Wnk1 and HSN2 requires not only OSR1 activity but also GSK3β.

We next analysed the interaction between GSK3B and HSN2, and found that HSN2 interacted more strongly with GSK3β than with WNK1 (Fig. 5C). Interestingly, HSN2 mutants associated more robustly with GSK3β than with wild-type HSN2 (Fig. 5D). From these results, we predicted that HSN2 mutants might suppress the binding of WNK1 and HSN2 to GSK3β by covering the binding sites of GSK3β. To confirm this hypothesis, we transiently expressed Flag-GSK3β and HA-WNK1 or HA-HSN2 with or without Myc-HSN2-delA and Myc-HSN2-insT mutants in HEK293T cells and then immunoprecipitated cell extracts with a Flag antibody. The binding of WNK1 and HSN2 to GSK3β was inhibited by expression of each HSN2 mutant (Fig. 5E,F). Moreover, these mutants also prevented the homo-dimerization of WNK1 and HSN2 respectively (Supplementary Fig. 3A,B), indicating that HSN2 mutants suppress the function of GSK3β in the WNK1/HSN2 pathway by preventing the interaction.

We then examined the effect of HSN2 mutants on GSK3β function in neurite outgrowth. As shown in Fig. 5G, GSK3β expression weakly induced neurite elongation of Neuro2A cells and WNK1 and HSN2 enhanced this induction under treatment with vehicle or NGF. In contrast, HSN2 mutants inhibited the GSK3β-induced neurite elongation (Fig. 5G). Consistent with these results, RT-PCR and qPCR analysis showed that GSK3β elevated...
NGF-induced *Lhx8* and *ChAT* expression and decreased *Gad1* expression (Fig. 5H). In addition, although wild-type HSN2 enhanced the expression of *Lhx8* and *ChAT*, HSN2 mutants suppressed the induction of these genes and facilitated *Gad1* expression (Fig. 5H). These results indicate that HSN2 mutants suppress the neurite outgrowth function of GSK3β by preventing the interaction of WNK1 and HSN2 with GSK3β.

**The function of HSN2 mutants and GSK3β in mouse primary neuron.** Finally, we analyzed the effect of WNK1, HSN2 and HSN2 mutants on neurite outgrowth of mouse primary cortical neuron. Consistent with the results from Neuro2A, neurite elongation of primary neuron was enhanced by WNK1 and HSN2 expression, but suppressed by HSN2 mutants (Fig. 6A). The qPCR analysis showed that *Lhx8* and *ChAT* expression were induced by WNK1 and HSN2 expression (Fig. 6B). However, *Gad1* expression was not changed by
Most mutations in HSN2-domains, for example, HSN2-delA and HSN2-insT19. We therefore consider that the C-terminal domain of HSN2 is a neuron-specific splice variant of the gene. These mutations include HSN2-delA and HSN2-insT14,19. Although cholinergic neural markers, and Lhx8 outgrowth. As expected, knockdown of WNK1 forms complexes with WNK1 and WNK4 to promote activation of itself and to activate the downstream mutants, and analysed their effects on the WNK/HSN2 pathway and neurite outgrowth using Neuro2A cells. 

HSANII is caused by mutations in a neuron-specific exon of WNK1 forms complexes with WNK1 and WNK4 to promote activation of itself and to activate the downstream mutants, and analysed their effects on the WNK/HSN2 pathway and neurite outgrowth using Neuro2A cells. WNK1, HSN2 and HSN2 mutants, and the repressive effect of HSN2 mutants on Lhx8 and ChAT expression was not confirmed (Fig. 6B). We also examined whether HSN2 mutants have dominant negative function for GSK3β induced the expression of Lhx8, ChAT and Gad1 in Neuro2A cells indicated in (D). The value of each gene from vehicle-treated cells under siCTRL treatment and from NGF-treated cells under siCTRL treatment was set to 1 and 100, respectively. (F) Neurite outgrowth of Neuro2A cells treated with 100 ng/ml NGF-containing FBS-free medium for 24 h. Cells were transiently transfected with siCTRL or siOsr1 and indicated vectors 24 h prior to treatment. (E) RT-PCR and qPCR analysis of mRNA levels of Lhx8, ChAT and Gad1 in Neuro2A cells indicated in (D). The value of each gene from empty vector-transfected, vehicle-treated cells and from empty vector-transfected, NGF-treated cells was set to 1 and 100, respectively. The band intensities of pSpak and pOsr1 in (A–C) by normalising intensities to the Spak and Osr1 signal, respectively. The measured values were shown in the graph under each immunoblot data.

Discussion

HSANII is a hereditary neuropathy that is characterized by sensory dysfunction, including loss of pain, touch, and temperature sensation21. HSANII is caused by mutations in a neuron specific exon of WNK1 forms complexes with WNK1 and WNK4 to promote activation of itself and to activate the downstream mutants, and analysed their effects on the WNK/HSN2 pathway and neurite outgrowth using Neuro2A cells. WNK1, HSN2 and HSN2 mutants, and the repressive effect of HSN2 mutants on Lhx8 and ChAT expression was not confirmed (Fig. 6B). We also examined whether HSN2 mutants have dominant negative function for GSK3β induced the expression of Lhx8, ChAT and Gad1 in Neuro2A cells indicated in (D). The value of each gene from vehicle-treated cells under siCTRL treatment and from NGF-treated cells under siCTRL treatment was set to 1 and 100, respectively. (F) Neurite outgrowth of Neuro2A cells treated with 100 ng/ml NGF-containing FBS-free medium for 24 h. Cells were transiently transfected with empty vector or kinase-negative Osr1 (OSR1K46M) 24 h prior to treatment. (G) RT-PCR and qPCR analysis of mRNA levels of Lhx8, ChAT and Gad1 in Neuro2A cells indicated in (F). The value of each gene from empty vector-transfected, vehicle-treated cells and from empty vector-transfected, NGF-treated cells was set to 1 and 100, respectively. The band intensities of pSpak and pOsr1 in (A–C) by normalising intensities to the Spak and Osr1 signal, respectively. The measured values were shown in the graph under each immunoblot data.
ion co-transporter, KCC2, and leads to abnormal neuromast development. Moreover, HSN2-deficient mice display increased KCC2 activity and decreased levels of Cl\(^{-}\) in nerves. These reports suggest that the regulation of KCC2 and ion-homeostasis by HSN2 is important for normal neural development. Here, we showed that the SPAK/OSR1 pathway was similarly activated by HSN2 and WNK1. Because WNK1-mediated activation of SPAK/OSR1 regulates the concentration of Cl\(^{-}\) ions in neurons through KCC2, the HSN2-SPAK/OSR1 pathway might regulate not only Lhx8 expression but also ion concentrations in neurons. Therefore, HSN2 mutation can dysregulate neurite outgrowth and ion-concentrations in neurons, and might cause loss of pain, touch and temperature sensation in HSANII patients.

Previous reports provide strong evidence that GSK3β has essential roles in neurodevelopmental processes. We have also reported GSK3β to be a positive downstream regulator in the WNK-SPAK/OSR1 pathway, which regulates neurite outgrowth. Here, we found that GSK3β also has a positive effect on the HSN2 pathway in Neuro2A cells and mouse primary cortical neurons. In contrast, HSN2-delA and HSN2-insT mutants suppressed GSK3β-mediated neurite elongation and specification. Interestingly, HSN2 mutants interacted more strongly with GSK3β than with wild-type HSN2 and prevented the binding of WNK1 and HSN2 to GSK3β. These results indicate that HSN2 mutants suppress GSK3β in neurite outgrowth by inhibiting its binding to WNK1 and HSN2. Conditional knockout mice of both GSK3α and GSK3β isoforms in neural progenitors has shown that GSK3s are essential for cortical neurogenesis; however, GSK3α-S21A/GSK3β-S29A double knock-in mice show that phosphorylation of GSK3s at their N-terminal serine residues is not necessary for neural polarization, including neurite outgrowth. In support of these findings, we reported that GSK3β is a downstream effector of the WNK-SPAK/OSR1 pathway in the regulation of neurite outgrowth, but neither WNK1 nor OSR1 kinases can phosphorylate GSK3β. Therefore, formation of GSK3β, WNK1/HSN2 and/or SPAK/OSR1 complexes has essential roles in neurite outgrowth and HSN2 mutants might cause HSANII by inhibiting formation of these complexes. However, further studies are needed to identify the precise mechanism of HSANII pathology.

In conclusion, our results demonstrate a critical role for HSN2 and suppressive effects of HSN2 mutants on the functions of GSK3β in neurite outgrowth. These findings may be beneficial for understanding the pathogenesis of HSANII.

**Materials and methods**

**Cell culture and treatment.** HEK293T and Neuro2A cells were cultured in DMEM (Gibco, Waltham, MA, USA) containing 10% foetal bovine serum (FBS). For neuronal differentiation, Neuro2A cells were treated with serum-free DMEM containing 100 ng/ml nerve growth factor (NGF) for 24 h. Images of neurite outgrowth
Figure 5. HSN2 mutants suppress GSK3β functions in neurite outgrowth. (A) Neurite outgrowth of Neuro2A cells treated with 100 ng/ml NGF-containing FBS-free medium for 24 h. Cells were transiently transfected with control siRNA (siCTL) or siGsk3β and indicated vectors 24 h prior to treatment. (B) RT-PCR and qPCR analysis of mRNA levels of Lhx8, ChAT and Gad1 in Neuro2A cells indicated in (A). The value of each gene from vehicle-treated cells under siCTL treatment and from NGF-treated cells under siCTL treatment was set to 1 and 100, respectively. (C,D) Binding analysis of WNK1 and HSN2 to GSK3β (C), and of HSN2-delA and HSN2-insT mutants to GSK3β (D). Cells were transiently transfected with indicated vectors and 48 h later lysates were immunoprecipitated with a Flag antibody for 4 h. Immunoprecipitates were subjected to immunoblotting assays with the indicated antibodies. (E,F) Interaction between WNK1 (E) or HSN2 (F) and GSK3β with and without HSN2-delA and HSN2-insT mutants was analysed in HEK293T cells by immunoprecipitation assays. Cells were transiently transfected with indicated vectors and 48 h later lysates were immunoprecipitated with a Flag antibody for 4 h. Immunoprecipitates were subjected to immunoblotting assays with the indicated antibodies. (G) Neurite elongation of Neuro2A cells treated with 100 ng/ml NGF-containing FBS-free medium for 24 h. Cells were transiently transfected with the indicated vectors 24 h prior to treatment. (H) RT-PCR and qPCR analysis of mRNA levels of Lhx8, ChAT and Gad1 in Neuro2A cells indicated in (G). The value of each gene from control vector-transfected and vehicle- or NGF-treated cells was set to 1 and 100, respectively.
Figure 6. The function of HSN2 mutants and GSK3β in mouse primary neuron. (A) Neurite outgrowth of mouse primary cortical neural cells expressing indicated plasmids. Average neurite length was quantified by ImageJ software with NeuronJ plugin. (B) qPCR analysis of mRNA levels of Lhx8, ChAT and Gad1 in primary neural cells indicated in (A). (C) Neurite elongation and average neurite length of mouse primary cortical neural cells expressing indicated plasmids. (D) The expression levels of Lhx8, ChAT and Gad1 mRNA in primary neural cells indicated in (C). (E,F) The expression levels of Lhx8, ChAT and Gad1 mRNA in non-treated Neuro2A cells expressing indicated plasmids. *P < 0.05, **P < 0.01.
from Neuro2A cells were obtained using Axioscope microscopes (Carl Zeiss, Germany), and the length of each neurite was quantified using ImageJ software with NeuronJ plugin.

**Antibodies.** Polyclonal antibodies, Anti-DDDDK, anti-Myc and anti-HA were obtained from Medical and Biological Laboratories (Japan). Monoclonal antibody, anti-GAPDH (5A12), was purchased from Wako (Japan). Anti-SPAK/OSR1 and anti-phospho-SPAK/OSR1 antibodies were prepared as previously described. These antibodies were used for immunoblotting at 1/1000. Anti-Myc (9B11) monoclonal antibody was purchased from Cell Signaling Technology (Danvers, MA, USA) and anti-Flag (M2) monoclonal antibody was obtained from Sigma-Aldrich (St. Louis, MO, USA), and these antibodies were used for immunoprecipitation at 1/500.

**Transfection of expression vectors and siRNA.** The coding sequence of the human HSN2 gene (NM_001184985) was cloned into the pRK5 vector with different molecular tags (Myc and HA). HSN2 mutants (2743delA and 3237_3238insT) were also cloned into pRK5. The sequence of these constructs was confirmed using a 3130 Genetic Analyzer (Applied Biosystems, Waltham, MA, USA). Other plasmids used were: HA-WNK1, Myc-WNK1, HA-WNK4, Flag-SPAK, Flag-OSR1, Flag-mOsr1K46M and Flag-GSK3β in pRK5. Cultured cells were transfected with these constructs using polyethyleneimine (Polysciences, Warrington, PA, USA). We also performed reverse transfection of siRNA using the TransIT-T2 Dynamic Delivery System (Mirus Bio, Madison, WI, USA). siRNA mouse target sequences were: Wnk1 5′-GAUAGGUGGCUCUA AUUA-3′ (NM_001185020.1 2701–2719 bp), Wnk4 5′-CUACUGGUGUCAGAAUGG-3′ (NM_175638.3 1218–1236 bp), Osr1 5′-GAUAAUUCUGUGUAAUAU-3′ (NM_133985.2 1698–1716 bp), Lhx8 5′-GGAAGAAUUGCCUUAAUC-3′ (NM_017013.2 1194–1212 bp) and Gsk3β 5′-GAAGAAGAAGCCAAAUUAUAU-3′ (NM_019827.7 2372–2390 bp).

**Reverse-transcription polymerase chain reaction (RT-PCR) analysis.** Total RNA was isolated using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). Double-strand cDNA was prepared from total RNA using oligonucleotide (dT), random primers and Moloney murine leukaemia virus reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Gapdh was used to normalize the cDNA samples. The intensity of each band was quantified using ImageJ software. For quantification, the intensity of each protein signal. The mouse sequences of the primer pairs for PCR were as follows: Wnk1 5′-AGA GATGGGCTCAGGTATCCAC-3′ and 5′-AACACACACGCTCAGCAGGAGCAG-3′, Wnk4 5′-AAG CTCGGTCGGCCAGTGAGGTGAT-3′ and 5′-GATCGGATGTCTCCTAGTCAAGATC-3′, Osr1 5′-TGGGCT TCTCATAAAGACAGAGGAC-3′ and 5′-TATCAGGAGCTTCACACCAAGATG-3′, Gsk3β 5′-GACAGCA AGCAATACACCATGTAGGG-3′ and 5′-TGAGTGTGCTCTTGAACAGGAG-3′, Lhx8 5′-GACCCAGCT GCCAATAAGTCACC-3′ and 5′-GACACACATCGAGCCAAACTCTC-3′, ChAT 5′-GATGTCCGACCCAC CACCTGTACCT-3′ and 5′-GACAAGATCGCACCCTACCTAGAGGAG-3′, Gad1 5′-CACCTCTCAACTCTT CTGCCGTAACAC-3′ and 5′-CAGTCACACGGATCTGCTCAGAG-3′, Gapdh 5′-GCCATCAGTCCAGCACC CAGAAGACTG-3′ and 5′-CATGAGGTCCACCACTGTTGCTG-3′.

**Quantitative real-time PCR.** Quantitative PCR was performed using a 7300 Real-Time PCR Cycler (Applied Biosystems) and THUNDERBIRD SYBR qPCR Mix (TOYOBO, Japan). The primer sequences were as follows: Wnk1 5′-AAGATGAAAGATATTTCCATC-3′ and 5′-TTCTTTAATATCTTCAATAG-3′, Wnk4 5′-TGG GGCACAAAGCAGCA-3′ and 5′-CTTATCCGCGGGAGTAGCA-3′, Hsn2 5′-GGAGATGTGCTCTGACC TATGC-3′ and 5′-CGATGACGGACATGGATG-3′. The sequences of the primer pairs for mouse Lhx8, ChAT, Gad1 and Gapdh were described previously. [37–39]. Gapdh was used to normalize the cDNA samples.

**Immunoprecipitation and immunoblot analysis.** Cells were lysed with TNE buffer [10 mM Tris–HCl (pH 7.4), 0.1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM DTT and protease inhibitor cocktail Complete (Roche, Switzerland)]. Lysates were pre-cleared with Protein A/G PLUS-agarse (Santa Cruz Biotechnology, Dallas, TX, USA) and immunoprecipitated with the indicated antibodies. For immunoblot analysis, cell lysates or immunoprecipitates were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride membranes (Merck Millipore, Germany). The membranes were probed with primary antibodies, followed by incubation with horseradish peroxidase-conjugated mouse or rabbit immunoglobulin G (GE Healthcare) and visualized using Immobilon Western (Merck Millipore). The protein bands were digitalized using the image analyser LAS-4000 Mini (Fujiﬁlm, Japan), and the intensity of each band was quantified using ImageJ software. For quantification, the intensity of the Gapdh band was used to normalise each protein signal.

**In vitro kinase assay.** OSR1 substrate CATCHtide was constructed in pGEX 4T-1 plasmid and GST-tagged CATCHtide was extracted from E. coli BL21 strain. Empty vector or Flag-mOsr1 was transfected into Neuro2A cells and cells were treated with vehicle, NGF (100 ng/ml) or sorbitol (500 mM) for indicated time. After stimulation, cells were lysed with TNE buffer and Flag-mOsr1 was immunoprecipitated with Flag-antibody and Protein A/G PLUS-agarse. Immunoprecipitates and GST-tagged CATCHtide were incubated in kinase buffer containing 10 mM HEPES (pH 7.4), 1 mM DTT, 5 mM MgCl₂, and 50 μM ATP at 37 °C for 30 min. Phosphorylated CATCHtide was subjected to SDS-PAGE including Phos-tag (Fujiﬁlm) and separated from non-phosphorylated CATCHtide in the gel. The intensity of each band was quantified using ImageJ software. For quantification, the intensity of the CBB-stained band was used to normalise each protein signal.
Preparation and treatment of mouse primary cortical neuron. Mouse primary cortical neurons were obtained as previously reported. The isolated cells were plated at 5 × 10⁴ cells in six well-plate with Neurobasal Medium (Gibco) containing B-27 Supplement (Gibco). Plate was pre-coated with Poly-d-Lysine (Sigma-Aldrich). After 3 days of plating, cells were transfected with indicated plasmids using TransIT-X2 Dynamic Delivery System. After 2 days of transfection, neurite elongation was observed by Axioscope microscopes, and the length of each neurites was quantified using ImageJ software with NeuronJ plugin. After the observation, mRNA was extracted in these cells for the quantitative PCR.

Statistical analysis. All experiments were independently repeated at least three times. Data are presented as the mean ± standard deviation (SD). Statistical analysis was performed with Student’s t-test using Microsoft Excel (Microsoft, DC, USA). P < 0.05 was considered statistically significant.

Data availability The data are available from the corresponding author upon request.

Received: 22 February 2022; Accepted: 12 September 2022
Published online: 23 September 2022

References
1. Xu, B. E. et al. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J. Biol. Chem. 275, 16795–16801 (2000).
2. Veríssimo, F. & Jordan, P. WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 20, 5562–5569 (2001).
3. Wilson, F. H. et al. Human hypertension caused by mutations in WNK kinases. Science 293, 1107–1112 (2001).
4. Piechotta, K., Lu, J. & Delpire, E. Cation chloride cotransporters interact with the stress-related kinases Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1). J. Biol. Chem. 277, 50812–50819 (2002).
5. Vitari, A. C., Deak, M., Morrice, N. A. & Alessi, D. R. The WNK1 and WNK4 protein kinases that are mutated in Gordon’s hyper-tension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Biochem. J. 391, 17–24 (2005).
6. Moriguchi, T. et al. WNK1 regulates phosphorylation of cation-cloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1. J. Biol. Chem. 280, 42685–42693 (2005).
7. Gagnon, K. B. E., England, R. & Delpire, E. Volume sensitivity of cation-Cl− cotransporters is modulated by the interaction of two kinases: Ste20-related proline-alanine-rich kinase and WNK4. Am. J. Physiol. Cell Physiol. 290, 134–142 (2006).
8. Yang, S. S. et al. Molecular pathogenesis of pseudohypaldosteronism type II: Generation and analysis of a Wnk4D561A/+ knockin mouse model. Cell Metab. 5, 331–344 (2007).
9. Xu, B. E. et al. Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J. Biol. Chem. 277, 48456–48462 (2002).
10. Wang, Z., Yang, C. L. & Ellison, D. H. Comparison of WNK4 and WNK1 kinase and inhibiting activities. Biochem. Biophys. Res. Commun. 317, 939–944 (2004).
11. Lenertz, L. Y. et al. Properties of WNK1 and implications for other family members. J. Biol. Chem. 280, 26653–26658 (2005).
12. Cope, G. et al. WNK1 affects surface expression of the ROMK potassium channel independent of WNK4. J. Am. Soc. Nephrol. 17, 1867–1874 (2006).
13. Thastrapr, J. O. et al. SPAK/OSR1 regulate NKCC1 and WNK activity: Analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation. Biochem. J. 441, 325–337 (2012).
14. Shekarabi, M. et al. Mutations in the nervous system-specific HS/N2 exon of WNK1 cause hereditary sensory neuropathy type II. J. Clin. Investig. 118, 2496–2505 (2008).
15. Vidal-Petiot, E. et al. A new methodology for quantification of alternatively spliced exons reveals a highly tissue-specific expression pattern of WNK1 isoforms. PLoS One 7, 1–9 (2012).
16. Futažka-Chromik, A., Kabzińska, D., Lipow ska, M., Kostera-Prusaczyk, A. & Kochański, A. A novel homozygous mutation in the WNK1/HSN2 gene causing Hereditary sensory neuropathy type 2. Acta Biochim. Pol. 59, 413–415 (2012).
17. Davidson, G. L. et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J. Neurol. 259, 1673–1685 (2012).
18. De Filette, J. et al. Polyneuropathy in a young Belgian patient: A novel heterozygous mutation in the WNK1/HSN2 gene. Neurof. Genet. 2, 1–8 (2016).
19. Yuan, J. H. et al. WNK1/HSN2 founder mutation in patients with hereditary sensory and autonomic neuropathy: A Japanese cohort study. Clin. Genet. 92, 659–663 (2017).
20. Rahmani, B. et al. A novel nonsense mutation in WNK1/HSN2 associated with sensory neuropathy and limb destruction in four siblings of a large Iranian pedigree. BMC Neurol. 18, 1–8 (2018).
21. Axelrod, F. B. & Gold-Von Simson, G. Hereditary sensory and autonomic neuropathies: Types II, III, and IV. Orphanet J. Rare Dis. 2, 1–12 (2007).
22. Bercier, V. et al. WNK1/HSN2 mutation in human peripheral neuropathy deregulates KCC2 expression and posterior lateral line development in zebrafish (Danio rerio). PLoS Genet. 9, e1003124 (2013).
23. Kahle, K. T. et al. Inhibition of the kinase WNK1/HSN2 ameliorates neuropathic pain by restoring GABA inhibition. Sci. Signal. 9, 1–9 (2016).
24. Tomioka, T. et al. LIM homeobox 8 (Lhx8) is a key regulator of the cholinergic neuronal function via a tropomyosin receptor kinase A (Trka)-mediated positive feedback loop. J. Biol. Chem. 289, 1000–1010 (2014).
25. Manabe, T. et al. L3/Lhx8 is involved in the determination of cholinergic or GABAergic cell fate. J. Neurochem. 94, 723–730 (2005).
26. Zhao, Y. et al. The LIM-homeobox gene Lhx8 is required for the development of many cholinergic neurons in the mouse forebrain. Proc. Natl. Acad. Sci. U.S.A. 100, 9005–9010 (2003).
27. Mori, T. et al. The LIM homeobox gene, L3/Lhx8, is necessary for proper development of basal forebrain cholinergic neurons. Eur. J. Neurosci. 19, 3129–3141 (2004).
28. Sato, A. & Shibuya, H. WNK signaling is involved in neural development via Lhx8/Awh expression. PLoS One 8, e55301 (2013).
29. Sato, A. & Shibuya, H. Glycogen synthase kinase 3β functions as a positive effector in the WNK signaling pathway. PLoS One 13, 1–11 (2018).
30. Vitari, A. C. et al. Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Biochem. J. 397, 223–231 (2006).
31. Friedel, P. et al. WNK1-regulated inhibitory phosphorylation of the KCC2 cotransporter maintains the depolarizing action of GABA in immature neurons. Sci. Signal. 8, 23–26 (2015).
32. Hur, E. M. & Zhou, F. Q. GSK3 signalling in neural development. Nat. Rev. Neurosci. 11, 539–551 (2010).
33. Jaworski, T., Banach-Kasper, E. & Gralec, K. GSK-3β at the intersection of neuronal plasticity and neurodegeneration. Neural Plast. 2019, Article 4209475 (2019).
34. Kim, W. Y. et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat. Neurosci. 12, 1390–1397 (2009).
35. Gärtner, A., Huang, X. & Hall, A. Neuronal polarity is regulated by glycogen synthase kinase-3 (GSK-3β) independently of Akt/ PKB serine phosphorylation. J. Cell Sci. 119, 3927–3934 (2006).
36. Meijering, E. et al. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytom. Part A 58, 167–176 (2004).
37. Zhang, Y., Cardell, L. O. & Adner, M. IL-1β induces murine airway 5-HT2A receptor hyperresponsiveness via a non-transcriptional MAPK-dependent mechanism. Respir. Res. 8, 1–12 (2007).
38. Huang, H. S. et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J. Neurosci. 27, 11254–11262 (2007).
39. Xu, B. et al. Proliferating cell nuclear antigen (PCNA) regulates primordial follicle assembly by promoting apoptosis of oocytes in fetal and neonatal mouse ovaries. PloS One 6, e16046 (2011).
40. Jin, M. et al. Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis. Commun. Biol. 4, 1–13 (2021).

Acknowledgements
We thank Hitoshi Okazawa (TMDU) and Hikari Tanaka (TMDU) for preparing mouse primary cortical neuron, and Atsushi Sato for providing the basis of this study. We also thank Jeremy Allen, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. This work was supported by Grants-in-Aid for scientific research from the Ministry of Education, Science, Sports and Culture of Japan (MEXT/JSPS KAKENHI Grant Number JP19K16782 (M.S.), and JP21K06165 (H.S.)) and Nanken-Kyoten, Tokyo Medical and Dental University (H.S.).

Author contributions
M.S. and H.S. designed the study, analysed the data, discussed the data and wrote the manuscript. M.S. performed all of the experiments.

Competing interests
The authors declare no competing interests.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-20271-y.

Correspondence and requests for materials should be addressed to H.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. In no event shall the publisher’s legal right, including but not limited to statistical analysis in published maps and institutional affiliations.

© The Author(s) 2022